Cited by 690Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 46 of the 51 references it cites were found in a registry or an index.

The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies

Open access

Scagliotti, Giorgio, Hanna, Nasser, Fossella, Frank, Sugarman, Katherine, Blatter, Johannes, Peterson, Patrick, Simms, Lorinda, Shepherd, Frances A.·2009·The Oncologist

DOI 10.1634/theoncologist.2008-0232

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Recent studies of pemetrexed have identified a predictive role for non-small cell lung cancer (NSCLC) histology. We further reviewed the differential efficacy of pemetrexed according to histology in two large, phase III NSCLC trials. METHODS: One study tested pemetrexed versus docetaxel in previously treated patients (n = 571) and the other tested cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemotherapy-naive patients (n = 1,725) with advanced NSCLC. Cox proportional hazard models were used to test for covariate-adjusted treatment-by-histology interactions (THIs) for overall survival (OS) and progression-free survival (PFS). For each histologic subgroup, the Kaplan-Meier method was used to estimate unadjusted within-arm medians, and Cox models were used to estimate covariate-adjusted between-arm hazard ratios (HRs). RESULTS: In both studies, treatment arms were well balanced for histology. THIs were statistically significant (p < .005) for both OS and PFS. Nonsquamous patients treated with pemetrexed-based therapy experienced longer survival than the comparators (HR, 0.78 and 0.84, respectively), whereas squamous patients had shorter survival (HR, 1.56 and 1.23, respectively). Whereas the efficacy of pemetrexed regimens differed according to histology, it did not differ for docetaxel or for cisplatin plus gemcitabine. Pemetrexed was well tolerated across histologic groups. CONCLUSIONS: The consistency of these results across studies confirms the predictive effect of histology for pemetrexed and the survival advantage for pemetrexed in patients with nonsquamous histology. These analyses suggest pemetrexed should not be recommended for the treatment of squamous cell carcinoma, but, because of efficacy and safety advantages, pemetrexed may be preferable to other agents for treatment of patients with nonsquamous NSCLC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2008-0232

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,524
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citation
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Self-citation
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Self-citation
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079

Show all 51 references

Research works printed but not linked: 2

Jiroutek, 1998, Prognostic factors in advanced non-small cell lung cancer (NSCLC): Analysis of Eastern Cooperative Oncology Group (ECOG) trials from 1981–1992, Proc Am Soc Clin Oncol, 17, 461a
National Cancer Institute, 1999, Common Toxicity Criteria v2.0 (CTC)

Sorted by citations

Items 501–600 of 687

A phase II study of S-1 in relapsed small cell lung cancer
Kudo, K., Ohyanagi, F., Horiike, A., Miyauchi, E., TAHANAKA, H., Yanagitani, N., Saito, R., KABURAKI, K., Sakatani, T., Horai, T., et al. (2013) · Molecular and Clinical Oncology · doi:10.3892/mco.2013.67 · Cited by 4
The predictive value of endobronchial ultrasonography with a guide sheath in the diagnosis of the histologic subtypes of lung cancer
Takeuchi, Y., Shinagawa, N., Kikuchi, E., Matsuno, Y., Hida, Y., Kaga, K., Oizumi, S., & Nishimura, M. (2016) · Respiratory Investigation · doi:10.1016/j.resinv.2016.05.003 · Cited by 4
Carcinoma de pulmón no microcítico
López, Á., Escalera, E., del Barco, E., Bellido, L., Cigarral, B., Barrios, B., Casado, D. I., Claros, J., Figuero, L., Olivares, A., et al. (2021) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2021.02.002 · Cited by 4
MTHFR polymorphism as a predictive biomarker for gastrointestinal and hematological toxicity in North Indian adenocarcinoma patients
Walia, H. K., Singh, N., & Sharma, S. (2021) · Journal of Chemotherapy · doi:10.1080/1120009x.2021.1997008 · Cited by 4
The Evolving role of the Pathologist in the Management of Lung Cancer
Gazdar, A. F. (2012) · Lung Cancer Management · doi:10.2217/lmt.12.43 · Cited by 4
Cytological reporting on lung FNA and small biopsy specimens in the era of personalized medicine
Mino-Kenudson, M. A. (2016) · Cancer Cytopathology · doi:10.1002/cncy.21793 · Cited by 4
Tumor response and clinical toxicity associated with second‐line chemotherapy regimens for advanced non‐squamous non‐small cell lung cancer: A retrospective cohort study
Hu, C., Wang, Y., Chen, J., Wu, S., Li, X., Wang, Y., Yang, Y., Rajan, N., Papadimitropoulos, M., Xiao, Q., et al. (2014) · Thoracic Cancer · doi:10.1111/1759-7714.12102 · Cited by 4
Carboplatin-Pemetrexed in Treatment of Patients with Recurrent/Metastatic Cancers of the Head and Neck; Superior Outcomes in Oropharyngeal Primaries
Malhotra, B., Bellile, E. L., Nguyen, N. P. T., Fung, V. K., Slack, M., Bilich, R., Papagerakis, S. M., & Worden, F. P. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2014.00362 · Cited by 4
Pemetrexed: Potential Role in the Adjuvant Chemotherapy of Non-Small Cell Lung Cancer
Vincent, M. D. (2009) · Current Drug Targets · doi:10.2174/138945010790030947 · Cited by 4
Study protocol: systematic review and meta-analysis of randomized controlled trials in first-line treatment of squamous non-small cell lung cancer
DeLozier, A. M., Brown, J., Natanegara, F., Zhao, L., Cui, Z. L., Able, S. L., Bowman, L., Treat, J., & Hess, L. M. (2014) · Systematic Reviews · doi:10.1186/2046-4053-3-102 · Cited by 4
Feasibility of computed tomography‐guided core needle biopsy in producing state‐of‐the‐art clinical management in C hinese lung cancer
Chen, H., Yang, J., Fang, L., Huang, M., Yan, H., Zhang, X., Xu, C., & Wu, Y.-L. L. C. (2013) · Thoracic Cancer · doi:10.1111/1759-7714.12076 · Cited by 4
Gemcitabine Plus Paclitaxel as Second-line Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
Baykara, M., Çoşkun, U., Berk, V., Özkan, M., Ma, K., Beneklı, M., Karaca, H., İnanç, M., Işıkdoğan, A., Sevinç, A., et al. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.10.5119 · Cited by 4
Maintenance therapy for advanced non-small-cell lung cancer: switch versus continuation
Joshi, M., Jiang, Y., & Belani, C. P. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.668530 · Cited by 4
Maintenance Therapy for Advanced-Non Small Cell Lung Cancer
Tarhini, A. A., & Argiris, A. E. (2010) · The Open Lung Cancer Journal · Cited by 4
Emerging role of thymidylate synthase for the pharmacogenomic selection of patients with thoracic cancer
Ceppi, P., Monica, V., Righi, L., Papotti, M. G., & Scagliotti, G. V. (2010) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp48481 · Cited by 4
Self-citation
Diverse and divergent functions of IL-32β and IL-32γ isoforms in the regulation of malignant pleural mesothelioma cell growth and the production of VEGF-A and CXCL8
Numasaki, M., Ito, K., Takagi, K., Nagashima, K., Notsuda, H., Ogino, H., Ando, R., Tomioka, Y., Suzuki, T., Okada, Y., et al. (2022) · Cellular Immunology · doi:10.1016/j.cellimm.2022.104652 · Cited by 3
Enhanced NSCLC subtyping and staging through attention-augmented multi-task deep learning: A novel diagnostic tool
Yang, R., Li, W., Yu, S., Wu, Z., Zhang, H., Liu, X., Tao, L., Li, X., Huang, J., & Guo, X. (2024) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2024.105694 · Cited by 3
Safety and efficacy of pemetrexed for patients with non-small cell lung cancer in the setting of renal impairment: a retrospective study
Shima, Y., Yoshida, H., Suminaga, K., Yoshida, H., Hashimoto, K., Ogimoto, T., Hosoya, K., Ajimizu, H., Funazo, T. Y., Nomizo, T., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13785-x · Cited by 3
Evaluation of molecular prognostic and predictive factors: an important step towards personalised treatment in non small cell lung cancer
Tartarone, A., Lerose, R., Gallucci, G., Ardito, R., & Aieta, M. (2011) · Medical Oncology · doi:10.1007/s12032-011-9992-y · Cited by 3
Second-line treatment in advanced non-small-cell lung cancer in the epidermal growth factor receptor wild-type population
Vázquez‐Estévez, S., Lázaro, M., Fírvida, J. L., Santomé, L., Afonso, J., Amenedo, M., & Casal, J. (2014) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000066 · Cited by 3
Pemetrexed as the first-line therapy for Chinese patients with advanced non-squamous non-small-cell lung cancer
Xu, B., Liu, P., Yin, Y., Liu, P., & Shu, Y. (2013) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2013.04.013 · Cited by 3
Assessing the clinical outcome of nab‐paclitaxel in C hinese patients with advanced non‐small‐cell lung cancer
Zeng, J., Yin, J., Yuan, D., Yang, W., Liang, W., Wu, G., & Song, Y. (2015) · The Clinical Respiratory Journal · doi:10.1111/crj.12394 · Cited by 3
Measurement of Quality of Life in Second-Line Patients with Advanced NSCLC without Targetable Mutations: A Review
Heigener, D. F., & Küchler, T. (2016) · Lung Cancer Management · doi:10.2217/lmt-2016-0010 · Cited by 3
A phase I study of nedaplatin, pemetrexed and thoracic intensity-modulated radiotherapy for inoperable stage III lung adenocarcinoma
Lu, Y., Gu, W., Deng, J., Yang, H., & Yang, W. (2016) · BMC Cancer · doi:10.1186/s12885-016-2800-5 · Cited by 3
Molecular Diagnosis of Lung Cancer
Popovska, S., Dineva, T., & Damyanova, P. (2017) · Journal of Biomedical and Clinical Research · doi:10.1515/jbcr-2017-0016 · Cited by 3
Systematic analysis of apoptosis-related genes in the prognosis of lung squamous cell carcinoma: a combined single-cell RNA sequencing study
Zhu, P., Yang, W., Wang, B., Zeng, T., Hu, Z., Zhang, D., Yang, Z., Wang, K., & Pu, J. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-23-1712 · Cited by 3
Elevated IL‑6/IL‑1Ra ratio as a prognostic biomarker of poor chemotherapy efficacy in Chinese patients with metastatic NSCLC, validated in a Caucasian patient cohort
Liu, F., Sansas, B., Pr�ville, X., Gineste, R., Wang, J., Yu, H., Xia, M., Micol, R., & Barraud, L. (2018) · Molecular and Clinical Oncology · doi:10.3892/mco.2018.1788 · Cited by 3
Feasibility Re-evaluation of 75 mg/m2 Docetaxel in Japanese Patients with Previously Treated Non-small Cell Lung Cancer
Yamada, K., Takeoka, H., Mizoguchi, Y., Yamashita, F., Yoshida, T., Zaizen, Y., Okayama, Y., Naito, Y., Azuma, K., & Hoshino, T. (2014) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt236 · Cited by 3
Recent Advances in Molecular Targeted Therapy for advanced Colorectal Cancer and Non–Small Cell Lung Cancer
Tanaka, T. (2012) · Journal of Physical Chemistry & Biophysics · doi:10.4172/2161-0398.1000108 · Cited by 3
TruSight Cancer Sequencing Panel reveals pharmacogenetic variants associated with sensitivity to chemotherapy in lung cancer
Chilingirova, N. P., Hammoudeh, Z., Balabanski, L., Ivanov, S. L., Vazharova, R., Nikolova, D. N., Kurteva, G. P., Toncheva, D. I., & Chilingirov, P. (2015) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-015-0244-2 · Cited by 3
Studies Regarding Quality Enhancement of Affairs by Pharmacist and Clinical Evaluation of Cancer Chemotherapy
Nakashima, M. (2015) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.41.289 · Cited by 3
Identifying Subsequent Therapies in Patients with Advanced Non–Small Cell Lung Cancer and Factors Associated with Overall Survival
Afanasjeva, J., Hui, R. L., Spence, M. M., Chang, J., Schottinger, J. E., Millares, M., & Rashid, N. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1826 · Cited by 3
Establishment of a first-line second-line treatment model for human pulmonary adenocarcinoma
Wang, L., Wang, Y., Guan, Q., Liu, Y. H., He, T., & Wang, J. (2016) · Oncology Letters · doi:10.3892/ol.2016.5299 · Cited by 3
The safety of second-line treatment options for non-small cell lung cancer
Rossi, A., Maione, P., Santabarbara, G., Sacco, P. C., Casaluce, F., Sgambato, A., Barzelloni, M. L., Palazzolo, G., & Gridelli, C. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1297795 · Cited by 3
Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial
Zhang, L., Belani, C. P., Zhang, P.-H., Wang, X., Yang, L., Orlando, M., & Wu, Y.-L. L. C. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.026 · Cited by 3
Automated classification of histological subtypes of NSCLC using support vector machines with radiomic features
Yamada, M., Arimura, H., Ninomiya, K., & Soufi, M. (2019) · International Forum on Medical Imaging in Asia (IFMIA) · doi:10.1117/12.2521511 · Cited by 3
Long-term exposure to pemetrexed induces chronic renal dysfunction in patients with advanced and recurrent non-squamous cell lung cancer: a retrospective study
Umehara, K., Yama, K., Koike, N., Takayama, S., Wakamoto, A., Hatuyama, T., Kobayashi, M., & Sato, H. (2020) · Renal Replacement Therapy · doi:10.1186/s41100-020-00292-x · Cited by 3
Singapore Cancer Network (SCAN) Guidelines for the Use of Systemic Therapy in Advanced Non-Small Cell Lung Cancer
The Singapore Cancer Network (SCAN) Lung Cancer Workgroup (2015) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v44n10p449 · Cited by 3
What is the role of maintenance therapy in the treatment of non-small cell lung cancer?
Jiang, Y., Owonikoko, T. K., Ramalingam, S. S., Khuri, F. R., & Belani, C. P. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010368045 · Cited by 3
2016: advances in medical oncology
Chubenko, V. A. (2017) · Practical oncology · doi:10.31917/1801115 · Cited by 3
Is Gefitinib Combined With Platinum-Doublet Chemotherapy a Counterpart to Osimertinib Monotherapy in Advanced EGFR-Mutated Non–Small-Cell Lung Cancer in the First-Line Setting?
Tanaka, T., Ishiki, H., Kubo, E., Yokota, S., Shimizu, M., Kiuchi, D., & Satomi, E. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02509 · Cited by 3
Data mining-based identification of epigenetic signatures with discrimination potential of lung adenocarcinoma and squamous cell carcinoma
Pang, W.-G., Ye, M., Chen, J., Zhang, L., & Wang, Z. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09216-y · Cited by 2
The Use of Systemic Treatment in the Maintenance of Patients with Non-small Cell Lung Cancer
Kulkarni, S., Vella, E. T., Coakley, N., Cheng, S., & Gregg, R. W. (2015) · Cited by 2
Weekly paclitaxel after first-line failure in patients with advanced non-small-cell lung cancer
Dipasquale, M., Murgia, V., Veccia, A., Brugnara, S., Caldara, A., Ferro, A., Frisinghelli, M., Maines, F., Trentin, C., Valduga, F., et al. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000482 · Cited by 2
Effects of Humidity and Light on Appearance Change and Folic Acid Content of Divided Panvitan® Powder for Prescription
Suzuki, H., Nakamura, T., Miyaura, S., Inooka, K., Yagi, T., Agatsuma, Y., Suzuki, T., Takamura, C., Suzuki, M., Murai, Y., et al. (2018) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.44.503 · Cited by 2
Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase–Low Squamous Cell Lung Cancer
Choi, M., Kim, H. T., Han, J., Lee, G. K., Lee, S.-H., Lim, K. Y., Joo, J., Won, H. J., Lee, J. S., & Lee, Y. (2020) · Cancer Research and Treatment · doi:10.4143/crt.2020.741 · Cited by 2
Adenocarcinoma
Kerr, K. M. (2012) · Molecular pathology library · doi:10.1007/978-1-4614-3197-8_13 · Cited by 2
Adequacy and Tissue Preservation of Small Biopsy and Cytology Specimens
Crapanzano, J. P., & Saqi, A. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1607-8_3 · Cited by 2
Prospective phase II study of cisplatin plus pemetrexed with maintenance of pemetrexed for advanced non‐squamous cell non‐small cell lung cancer in J apan
Asami, K., Kawahara, M., Hirashima, T., Suzuki, H., Okishio, K., Omachi, N., Tamiya, M., Tamiya, A., Hirooka, A., Nakao, K., et al. (2014) · Thoracic Cancer · doi:10.1111/1759-7714.12091 · Cited by 2
Clinical observation of pemetrexed on advanced non-small-cell lung cancer
Zheng, Y., Ge, W., Zhang, L., Zhao, Z., & Jie, F. (2011) · The Chinese-German Journal of Clinical Oncology · doi:10.1007/s10330-011-0757-z · Cited by 2
Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis
Fragoulakis, V., Pallis, A. G., Kateilidou, Maniadakis, N. M., & Georgoulias, V. (2012) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s33608 · Cited by 2
Gemcitabine Plus Vinorelbine as the Second-Line Treatment and Beyond in Elderly Patients with Platinum-Pretreated Advanced Non-Small Cell Lung Cancer
Go, S., Lee, W. S., Lee, G., Kang, J. H., Kang, M. H., Song, H., Lee, A., Lee, U. S., Choi, H. J., & Kim, H. (2014) · Chemotherapy · doi:10.1159/000381636 · Cited by 2
Maintenance therapy for patients with advanced non-small cell lung cancer: Who to treat and how to treat?
Rothschild, S. I., & Gautschi, O. P. (2011) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-011-0242-y · Cited by 2
Personalized Choice of Maintenance Therapies in Non-Small-Cell Lung Cancer
Blais, N., & Corrales, L. (2012) · Current Oncology · doi:10.3747/co.19.1068 · Cited by 2
The current state of pemetrexed in ovarian cancer
Miller, R. E., & Banerjee, S. N. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.820703 · Cited by 2
A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001)
Hattori, Y., Satouchi, M., Katakami, N., Fujita, S., Kaji, R., Hata, A., Urata, Y., Shimada, T., Uchida, J., Tomii, K., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2290-y · Cited by 2
Therapeutic Options in Advanced Squamous Cell Lung Carcinoma
Tan, H.-L., Ang, Y. L. E., & Soo, R. A. (2015) · Lung Cancer Management · doi:10.2217/lmt.15.7 · Cited by 2
Differential efficacy of docetaxel according to non-small cell lung cancer histology and the therapeutic effect of epidermal growth factor receptor tyrosine kinase inhibitors
Miura, S., Murakami, H., Tamiya, A., Morii, S., Akamatsu, H., Ono, A., SYUKUYA, T., Kenmotsu, H., Tsuya, A., Nakamura, Y., et al. (2011) · Oncology Letters · doi:10.3892/ol.2011.400 · Cited by 2
Pemetrexed as indispensable drug for the treatment of non-squamous non-small cell lung cancer; the role in induction and maintenance therapy
(2014) · Cancer Cell & Microenvironment · doi:10.14800/ccm.157 · Cited by 2
Immunotherapy for Non-Small Cell Lung Cancer - Finally a Hint of Hope
Recondo, G., Recondo, G., Galanternik, F., Greco, M., Vega, M., Diaz-Canton, E. A., & Valsecchi, M. E. (2016) · Reviews on Recent Clinical Trials · doi:10.2174/1574887111666160330121349 · Cited by 2
Acute Respiratory Deterioration After Second-line Chemotherapy in Patients with Interstitial Pneumonia Associated with Lung Cancer
Isobe, K., Hata, Y., Kaburaki, K., Sakamoto, S., Takai, Y., Tochigi, N., Iyoda, A., & Homma, S. A. (2014) · Haigan · doi:10.2482/haigan.54.761 · Cited by 2
Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma
Guo, L., Zhang, M., Zhang, H., Zhou, J., Cai, X., Yu, L., Guo, Q., Yang, N., Zhao, J., Xie, Z., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01568 · Cited by 2
Exonuclease 1 genetic variant is associated with clinical outcomes of pemetrexed chemotherapy in lung adenocarcinoma
Hong, M. J., Park, J. E., Lee, S. Y., Lee, J. H., Choi, J. E., Kang, H., Do, S. K., Jeong, J. Y., Shin, K. M., Lee, W. K., et al. (2022) · Journal of Cancer · doi:10.7150/jca.78498 · Cited by 2
A multicenter, open‐label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non‐small cell lung cancer
Yabuki, Y., Hanibuchi, M., Takeuchi, E., Haku, T., Kanematsu, T., Nishimura, N., Toyoda, Y., Mitsuhashi, A., Otsuka, K., Sato, S., et al. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15115 · Cited by 2
Mutation profile and programmed death ligand 1 status of patients with non‐small cell lung cancer diagnosed with “adenocarcinoma” and “non‐small cell carcinoma favor adenocarcinoma”
Shigeta, N., Yokose, T., Murakami, S., Isaka, T., Shinada, K., Yoshioka, E., Narita, A., Katakura, K., Kondo, T., Kato, T., et al. (2024) · Thoracic Cancer · doi:10.1111/1759-7714.15214 · Cited by 2
Dose-Escalation Study of Thoracic Radiotherapy in Combination With Pemetrexed Plus Cisplatin in Japanese Patients With Locally Advanced Nonsquamous Non–Small Cell Lung Cancer
Niho, S., Nokihara, H., Nihei, K., Akimoto, T., Sumi, M., Ito, Y., Yoh, K., Goto, K., Ohmatsu, H., Horinouchi, H., et al. (2014) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000030 · Cited by 2
A long‐term survivor keeping in a complete response without treatment after pemetrexed maintenance therapy for advanced non‐squamous non‐small cell lung cancer
Furugen, M., Shibahara, D., Kiyuna, T., Kami, W., Miyagi, K., Haranaga, S., Kubota, T., Matsumoto, H., Yoshimi, N., & Fujita, J. (2020) · Clinical Case Reports · doi:10.1002/ccr3.3650 · Cited by 2
Pemetrexed Plus Bevacizumab for Second-Line Therapy of Non–Small-Cell Lung Cancer: The Importance of Patient Selection
Araújo, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7351 · Cited by 2
Management of Locally Advanced Non-Small Cell Lung Cancer
Shiarli, A.-M., Patel, P. H., & McDonald, F. (2021) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00206-7 · Cited by 2
Metabolic and multi-model intravoxel incoherent motion parameters based 18F-FDG PET/MRI for predicting subtypes of inoperable non-small cell lung cancer
Huang, Z., Wang, H., Fang, T., Chen, Y., Fan, H., Li, X., Fu, F., Yuan, J., Yang, Y., Wang, Z., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13543-z · Cited by 1
Revealing roles of PANoptosis-related genes in prognosis and molecular subtypes in lung squamous cell carcinoma by integrated bioinformatic analyses and experiments
Chen, Y., & Wang, M. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01696-x · Cited by 1
Real-World Treatment Patterns and Survival in Patients with Advanced Non-Small Cell Lung Cancer: An Italian Retrospective Cohort Study
Delmonte, A., Gentili, N., Roncadori, A., Maltoni, R., Danesi, V., Hindocha, P., Leal, C., Oikonomou, S., Mella, M., Lay-Flurrie, S. L., et al. (2026) · Cancers · doi:10.3390/cancers18030538 · Cited by 1
Personalisierte medikamentöse Therapie des fortgeschrittenen nichtkleinzelligen Lungenkarzinoms
Köhler, J., & Schüler, M. (2011) · Der Onkologe · doi:10.1007/s00761-011-2036-6 · Cited by 1
The molecular approach to diagnosis in lung cancer
Moore, D. A., & Quesne, J. P. C. L. (2015) · British Journal of Hospital Medicine · doi:10.12968/hmed.2015.76.5.c74 · Cited by 1
Efficacy and Tolerability of the Bevacizumab/carboplatin/paclitaxel Combination Therapy as First-line or Non-first-line Therapy for Non-small-cell Lung Cancer
Nakashima, M., Ohnishi, R., Kobayashi, M., Suzuki, T., Yasuda, S., Sano, K., Goto, T., Mishima, N., Kato, T., & Sugiyama, T. (2012) · Haigan · doi:10.2482/haigan.52.1007 · Cited by 1
Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment
Shi, S., Hu, R., Qi, J.-L., Tang, X., Tian, J., Li, R., & Chang, C. (2013) · Medical Oncology · doi:10.1007/s12032-013-0550-7 · Cited by 1
Pemetrexed in Non-Small-Cell Lung Cancer
Dediu, M., Alexandru, A., & Bratu, F. (2014) · Lung Cancer Management · doi:10.2217/lmt.14.16 · Cited by 1
S-1 Combined with Bi-Weekly Docetaxel for Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy: A Phase II Study of North Japan Lung Cancer Group (NJLCG0701)
Ishimoto, O., Sakakibara, T., Maemondo, M., Inoue, A., Matsubara, N., Morikawa, N., Okudera, K., Usui, K., Suzuki, T., Nukiwa, T., et al. (2012) · Cancer and Clinical Oncology · doi:10.5539/cco.v1n1p108 · Cited by 1
The Effectiveness of Maintenance Pharmacotherapies for Non-Small Cell Lung Cancer
Ahn, M., Sun, J., Ahn, J. S., & Park, K. (2012) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s8001 · Cited by 1
Traitement adjuvant des cancers bronchiques non à petite cellules : tolérance de l’association platine-pemetrexed
Gauvain, C., Créquit, P., Rousseau-Bussac, G., Ganoun, A., Baud, M., & CHOUAID, C. (2014) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2013.10.646 · Cited by 1
Dose erlotinib add beneficial effect on cytotoxic agent for patients with pretreated advanced non-small cell lung cancer?
(2014) · Cancer Cell & Microenvironment · doi:10.14800/ccm.57 · Cited by 1
Lung cancer: from staging to treatment – a summary of an international meeting
Houtte, P. V. (2009) · Expert Review of Respiratory Medicine · doi:10.1586/ers.09.17 · Cited by 1
Histologic Classification and Its Need for Treatment of Lung Cancer
Moreira, A. L., & Travis, W. D. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1607-8_1 · Cited by 1
Démembrement des adénocarcinomes bronchopulmonaires : le point de vue du pathologiste
Weingertner, N., & Chenard, M. (2015) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(16)30010-6 · Cited by 1
[Pemetrexed combined DDP in the treatment of advanced non-small cell lung cancer: a case report and literature review].
Zhao, C., Sun, H., Yang, Y., & Dai, X. (2010) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2010.07.18 · Cited by 1
Traitements de deuxième ligne du cancer bronchique non à petites cellules métastatique : quels choix aujourd’hui ? Quelles perspectives demain ?
Greillier, L., & Barlési, F. (2012) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2011.12.006 · Cited by 1
Recent advances in the management of advanced non–small-cell lung cancer
Aggarwal, C., & Langer, C. J. (2013) · Community Oncology · doi:10.12788/j.cmonc.0005 · Cited by 1
Clinical Presentation and Prognostic Factors in Lung Cancer
Nackaerts, K., Park, K., Sun, J., & Fong, K. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52357-8.00020-2 · Cited by 1
Concurrent chemoradiotherapy with cisplatin + S-1 versus cisplatin + other third-generation agents for locally advanced non-small-cell lung cancer: a meta-analysis of individual participant data
Taniguchi, Y., Okamoto, H., Shimokawa, T., Sasaki, T., Seto, T., Niho, S., Ohe, Y., & Saigusa, Y. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-01828-z · Cited by 1
Predicting Biomarkers and Therapeutic Targets in Cancer
Ningthoujam, R., Chanu, N. B., Anumala, V., Babu, P. J., Pradhan, S., Panda, M. K., Heisnam, P., & Singh, Y. D. (2022) · Studies in computational intelligence · doi:10.1007/978-981-16-9221-5_13 · Cited by 1
Clinical efficacy and safety of pemetrexed with or without either Bevacizumab or Pembrolizumab in patients with metastatic nonsquamous non–small cell carcinoma
Kwok, W. C., Cheong, T. F., Chiang, K. Y., Ho, J., Lam, D. C. L., Ip, M., & Tam, T. C. C. (2022) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13658 · Cited by 1
Bedeutung der Histologie für die Therapie des fortgeschrittenen, nicht-kleinzelligen Bronchuskarzinoms
Rothschild, S. I., Betticher, D., Ochsenbein, A. F., Stahel, R. A., Bubendorf, L., Gugger, M., Brutsche, M. H., Pless, M., & Gautschi, O. P. (2010) · Swiss Medical Forum ‒ Schweizerisches Medizin-Forum · doi:10.4414/smf.2010.07186 · Cited by 1
Novel Taxanes/Epothilones
Dy, G. K. (2010) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000391379.94307.d1 · Cited by 1
Thymidylate synthase inhibitors for thoracic tumors
Peters, G. J., Galvani, E., Jansen, G., Assaraf, Y. G., & Giovannetti, E. (2013) · Pteridines · doi:10.1515/pterid-2013-0018 · Cited by 1
Targeted therapy and tailored chemotherapy for advanced non-small cell lung cancer
Yun, T. (2009) · The Korean Journal of Internal Medicine · Cited by 1
Results of treatment of patients with locally advanced and metastatic non-squamous cell non-small-cell lung carcinoma with pemetrexed (by own experience)
Vladimirova, L. Y., Эдуардовна, С. А., Kabanov, S. N., & Kalabanova, E. A. (2016) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2016-15-1-26-30 · Cited by 1
Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer)
Bennouna, J., Barlési, F., Dô, P., Dumont, P., Cadranel, J. L., Debieuvre, D., Hilgers, W., Molinier, O., Quoix, É., Raimbourg, J., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000394 · Cited by 1
First-Line Therapy for Wild-Type Patients
Jelinek, M. J., & Patel, J. D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55433-6.00005-5 · Cited by 1
New Insights into the Discovery of Novel Drugs to Treat Human Pulmonary Adenocarcinoma
Wang, Y., Zhang, H., Chen, Y., & Wang, L. (2019) · Journal of Cancer Therapy · doi:10.4236/jct.2019.102014 · Cited by 1
Applications of biomarkers for different purposes in drug development
Halim, A. B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816121-0.00002-7 · Cited by 1

Authors: Scagliotti, G., Hanna, N., Fossella, F., Sugarman, K., Blatter, J., Peterson, P., Simms, L., & Shepherd, F. A.
Affiliations: University of Turin (IT)
Indiana University Indianapolis (US)
The University of Texas MD Anderson Cancer Center (US)
Eli Lilly (United States) (US)
Eli Lilly (Germany) (DE)
Eli Lilly (Canada) (CA)
University of Toronto (CA)
Corresponding author: Scagliotti, Giorgio
ORCID: Scagliotti, Giorgio
Hanna, Nasser
Peterson, Patrick
Shepherd, Frances A.
Venue: The Oncologist
Publisher: Oxford University Press (OUP)
Published: 2009-02-16
Volume: 14
Issue: 3
Pages: 253-263
ISSN: 1083-7159 (ISSN-L)
1549-490X
DOI: 10.1634/theoncologist.2008-0232
OpenAlex: W2139939379
Cited by: 690
References: 51
Citations by year: 2026: 5 · 2025: 8 · 2024: 10 · 2023: 15 · 2022: 21 · 2021: 15 · 2020: 27 · 2019: 29 · 2018: 30 · 2017: 42 · 2016: 46 · 2015: 41 · 2014: 69 · 2013: 72 · 2012: 71
FWCI: 72.97
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Locations: The Oncologist (publishedVersion)
PubMed (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
INFM-OAR (INFN Catania) (submittedVersion, other-oa)
Funders: Eli Lilly and Company
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: pemetrexed, non-small cell lung cancer, tumor histology, squamous cell carcinoma, docetaxel, overall survival, progression-free survival, predictive biomarkers
MeSH terms: Pemetrexed, Docetaxel, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Deoxycytidine, Female, Glutamates, Guanine, Humans, Lung Neoplasms, Male, Middle Aged, Randomized Controlled Trials as Topic, Taxoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks